Clinical pharmacogenetics in oncology

The paradigm of molecular targeted therapies

Giannis Mountzios, Despina Sanoudou, Konstantinos N. Syrigos

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Even though treatment of several types of solid tumors has improved in the past few years with the introduction of molecular targeted agents in the therapeutic armamentarium of the medical oncologist, response rates to these agents are generally modest. Increasing evidence is now revealing that genetic factors are affecting patients' response to these therapeutic agents as well as the frequency and intensity of toxic reactions. Importantly, pharmacogenetic analysis is now required for the administration of several molecular targeted agents in clinical practice. For the vast majority of these agents, however, data remain purely experimental. Herein, we provide an overview of the genetic changes (mutations and polymorphisms) that have been associated with response to treatment with anticancer molecular targeted agents. Special emphasis is given on molecules (monoclonal antibodies and tyrosine kinase inhibitors) that target critical mediators in the epidermal growth factor receptor (EGFR), the human epidermal growth factor receptor 2 (HER2/ERBB2/NEU) and the vascular endothelial growth factor receptor (VEGFR) pathways. The true clinical utility of these applications remains to be proven in future prospective, randomized clinical trials in large patient cohorts of all different ethnic backgrounds.

Original languageEnglish
Pages (from-to)2184-2193
Number of pages10
JournalCurrent Pharmaceutical Design
Volume16
Issue number20
DOIs
Publication statusPublished - 20 Aug 2010
Externally publishedYes

Fingerprint

Molecular Targeted Therapy
Pharmacogenetics
Vascular Endothelial Growth Factor Receptor
Poisons
Therapeutics
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Randomized Controlled Trials
Monoclonal Antibodies
Mutation
Neoplasms

Keywords

  • Cancer
  • Individualized treatment
  • Molecular targeted therapy
  • Pharmacogenetics

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Clinical pharmacogenetics in oncology : The paradigm of molecular targeted therapies. / Mountzios, Giannis; Sanoudou, Despina; Syrigos, Konstantinos N.

In: Current Pharmaceutical Design, Vol. 16, No. 20, 20.08.2010, p. 2184-2193.

Research output: Contribution to journalArticle

Mountzios, Giannis ; Sanoudou, Despina ; Syrigos, Konstantinos N. / Clinical pharmacogenetics in oncology : The paradigm of molecular targeted therapies. In: Current Pharmaceutical Design. 2010 ; Vol. 16, No. 20. pp. 2184-2193.
@article{3647f29772dd4d44a9b4ece215aa75ab,
title = "Clinical pharmacogenetics in oncology: The paradigm of molecular targeted therapies",
abstract = "Even though treatment of several types of solid tumors has improved in the past few years with the introduction of molecular targeted agents in the therapeutic armamentarium of the medical oncologist, response rates to these agents are generally modest. Increasing evidence is now revealing that genetic factors are affecting patients' response to these therapeutic agents as well as the frequency and intensity of toxic reactions. Importantly, pharmacogenetic analysis is now required for the administration of several molecular targeted agents in clinical practice. For the vast majority of these agents, however, data remain purely experimental. Herein, we provide an overview of the genetic changes (mutations and polymorphisms) that have been associated with response to treatment with anticancer molecular targeted agents. Special emphasis is given on molecules (monoclonal antibodies and tyrosine kinase inhibitors) that target critical mediators in the epidermal growth factor receptor (EGFR), the human epidermal growth factor receptor 2 (HER2/ERBB2/NEU) and the vascular endothelial growth factor receptor (VEGFR) pathways. The true clinical utility of these applications remains to be proven in future prospective, randomized clinical trials in large patient cohorts of all different ethnic backgrounds.",
keywords = "Cancer, Individualized treatment, Molecular targeted therapy, Pharmacogenetics",
author = "Giannis Mountzios and Despina Sanoudou and Syrigos, {Konstantinos N.}",
year = "2010",
month = "8",
day = "20",
doi = "10.2174/138161210791792859",
language = "English",
volume = "16",
pages = "2184--2193",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "20",

}

TY - JOUR

T1 - Clinical pharmacogenetics in oncology

T2 - The paradigm of molecular targeted therapies

AU - Mountzios, Giannis

AU - Sanoudou, Despina

AU - Syrigos, Konstantinos N.

PY - 2010/8/20

Y1 - 2010/8/20

N2 - Even though treatment of several types of solid tumors has improved in the past few years with the introduction of molecular targeted agents in the therapeutic armamentarium of the medical oncologist, response rates to these agents are generally modest. Increasing evidence is now revealing that genetic factors are affecting patients' response to these therapeutic agents as well as the frequency and intensity of toxic reactions. Importantly, pharmacogenetic analysis is now required for the administration of several molecular targeted agents in clinical practice. For the vast majority of these agents, however, data remain purely experimental. Herein, we provide an overview of the genetic changes (mutations and polymorphisms) that have been associated with response to treatment with anticancer molecular targeted agents. Special emphasis is given on molecules (monoclonal antibodies and tyrosine kinase inhibitors) that target critical mediators in the epidermal growth factor receptor (EGFR), the human epidermal growth factor receptor 2 (HER2/ERBB2/NEU) and the vascular endothelial growth factor receptor (VEGFR) pathways. The true clinical utility of these applications remains to be proven in future prospective, randomized clinical trials in large patient cohorts of all different ethnic backgrounds.

AB - Even though treatment of several types of solid tumors has improved in the past few years with the introduction of molecular targeted agents in the therapeutic armamentarium of the medical oncologist, response rates to these agents are generally modest. Increasing evidence is now revealing that genetic factors are affecting patients' response to these therapeutic agents as well as the frequency and intensity of toxic reactions. Importantly, pharmacogenetic analysis is now required for the administration of several molecular targeted agents in clinical practice. For the vast majority of these agents, however, data remain purely experimental. Herein, we provide an overview of the genetic changes (mutations and polymorphisms) that have been associated with response to treatment with anticancer molecular targeted agents. Special emphasis is given on molecules (monoclonal antibodies and tyrosine kinase inhibitors) that target critical mediators in the epidermal growth factor receptor (EGFR), the human epidermal growth factor receptor 2 (HER2/ERBB2/NEU) and the vascular endothelial growth factor receptor (VEGFR) pathways. The true clinical utility of these applications remains to be proven in future prospective, randomized clinical trials in large patient cohorts of all different ethnic backgrounds.

KW - Cancer

KW - Individualized treatment

KW - Molecular targeted therapy

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=77955635784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955635784&partnerID=8YFLogxK

U2 - 10.2174/138161210791792859

DO - 10.2174/138161210791792859

M3 - Article

VL - 16

SP - 2184

EP - 2193

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 20

ER -